Akebia stock jumps as FDA clears renal anemia therapy (NASDAQ:AKBA)

Published on 28 Mar 2024 on Seeking Alpha

Akebia Therapeutics (AKBA) receives FDA approval for Vafseo tablets, leading to a 25% surge in...

Read the rest of the article

Start tracking your investments with Statfolio

Here are three stocks added to the Zacks Rank #24 (Strong Sell) List today: Akebia Therapeutics, ...

Zacks · via Yahoo Finance 3 Jan 2025

Total Revenue: $43.6 million in Q2 2024. Auryxia Net Product Revenue: $41.2 million in Q2 2024,...

GuruFocus.com · via Yahoo Finance 9 Oct 2024

Revenue: Reported at $32.6 million for Q1 2024, a decrease from $40.0 million in Q1 2023, falling...

GuruFocus.com via Yahoo Finance 13 May 2024

The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to s...

Simply Wall St. via Yahoo Finance 13 May 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript May 9, 2024 Akebia Thera...

Insider Monkey via Yahoo Finance 11 May 2024

With the business potentially at an important milestone, we thought we'd take a closer look at Ak...

Simply Wall St. via Yahoo Finance 28 Apr 2024

Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for...

Benzinga via Yahoo Finance 29 Mar 2024

Akebia Therapeutics, Inc. AKBA announced that the FDA has approved its Vafseo (vadadustat) tablet...

Zacks via Yahoo Finance 28 Mar 2024

Akebia Therapeutics (AKBA) receives FDA approval for Vafseo tablets, leading to a 25% surge in...

Seeking Alpha 28 Mar 2024

, opens new tab drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialy...

Reuters 28 Mar 2024